FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2765437031> ?p ?o ?g. }

• W2765437031 endingPage "A467" @default.
• W2765437031 startingPage "A467" @default.
• W2765437031 abstract "Literature on restrictions on access to innovative oncology treatments in Russia is limited. This research aims to assess the restrictions placed on targeted NSCLC therapies and the related impact on prescribing. Data were drawn from the Adelphi Disease Specific Programme (DSP) in NSCLC conducted in Q1 2017. Medical oncologists, actively managing patients with NSCLC, completed a workload questionnaire, survey and patient record forms (PRFs) for up to the next 10 of their consulting NSCLC patients. In addition to clinical considerations, participating oncologists were asked their perceptions of the level of administrative controls for targeted treatments. 53 physicians provided perceptions of access restrictions and completed 329 PRFs. Within the epidermal growth factor receptor (EGFR) class, gefitinib was considered available according to approved indication without further restriction by 59% of physicians, decreasing to 54% for erlotinib and 11% for afatinib. 37% considered gefitinib available, but with restrictions beyond the approved indication, increasing to 39% for erlotinib and 48% for afatinib. Levels of prescribing followed perceived access with 31 of 329 patients currently receiving gefitinib, 9 erlotinib and 2 afatinib. Ease of reimbursed access was considered an important criterion of product choice (mean score of 5.8, on scale of 1-7 with 7 being very important); >50% physicians included this in their top 5 considerations in first-line treatment selection with just under half reporting the same in later-line settings. A correlation between prescribing levels and perceived access was observed within the EGFR class in Russia; this finding is consistent with the reported importance of reimbursed access in product selection. Reasons for perceived differences in access were not explored; the extent to which they relate to administrative controls, time since launch, familiarity or other factors should be explored to understand factors affecting patients’ access to innovative oncology products." @default.
• W2765437031 created "2017-11-10" @default.
• W2765437031 creator A5004901169 @default.
• W2765437031 creator A5009396013 @default.
• W2765437031 creator A5037191682 @default.
• W2765437031 creator A5039224084 @default.
• W2765437031 date "2017-10-01" @default.
• W2765437031 modified "2023-10-16" @default.
• W2765437031 title "Access Perceptions: A Key Driver Of Non-Small Cell Lung Cancer (NSCLC) Targeted Therapy Prescription In Russia" @default.
• W2765437031 doi "https://doi.org/10.1016/j.jval.2017.08.388" @default.
• W2765437031 hasPublicationYear "2017" @default.
• W2765437031 type Work @default.
• W2765437031 sameAs 2765437031 @default.
• W2765437031 citedByCount "0" @default.
• W2765437031 crossrefType "journal-article" @default.
• W2765437031 hasAuthorship W2765437031A5004901169 @default.
• W2765437031 hasAuthorship W2765437031A5009396013 @default.
• W2765437031 hasAuthorship W2765437031A5037191682 @default.
• W2765437031 hasAuthorship W2765437031A5039224084 @default.
• W2765437031 hasBestOaLocation W27654370311 @default.
• W2765437031 hasConcept C121608353 @default.
• W2765437031 hasConcept C126322002 @default.
• W2765437031 hasConcept C143998085 @default.
• W2765437031 hasConcept C2775832928 @default.
• W2765437031 hasConcept C2776256026 @default.
• W2765437031 hasConcept C2778087573 @default.
• W2765437031 hasConcept C2779438470 @default.
• W2765437031 hasConcept C2780580887 @default.
• W2765437031 hasConcept C2780586478 @default.
• W2765437031 hasConcept C512399662 @default.
• W2765437031 hasConcept C71924100 @default.
• W2765437031 hasConceptScore W2765437031C121608353 @default.
• W2765437031 hasConceptScore W2765437031C126322002 @default.
• W2765437031 hasConceptScore W2765437031C143998085 @default.
• W2765437031 hasConceptScore W2765437031C2775832928 @default.
• W2765437031 hasConceptScore W2765437031C2776256026 @default.
• W2765437031 hasConceptScore W2765437031C2778087573 @default.
• W2765437031 hasConceptScore W2765437031C2779438470 @default.
• W2765437031 hasConceptScore W2765437031C2780580887 @default.
• W2765437031 hasConceptScore W2765437031C2780586478 @default.
• W2765437031 hasConceptScore W2765437031C512399662 @default.
• W2765437031 hasConceptScore W2765437031C71924100 @default.
• W2765437031 hasIssue "9" @default.
• W2765437031 hasLocation W27654370311 @default.
• W2765437031 hasOpenAccess W2765437031 @default.
• W2765437031 hasPrimaryLocation W27654370311 @default.
• W2765437031 hasRelatedWork W1994508061 @default.
• W2765437031 hasRelatedWork W2049303357 @default.
• W2765437031 hasRelatedWork W2186047679 @default.
• W2765437031 hasRelatedWork W2542769082 @default.
• W2765437031 hasRelatedWork W2810945895 @default.
• W2765437031 hasRelatedWork W2888534976 @default.
• W2765437031 hasRelatedWork W2906574801 @default.
• W2765437031 hasRelatedWork W3042289395 @default.
• W2765437031 hasRelatedWork W3175282903 @default.
• W2765437031 hasRelatedWork W4281690819 @default.
• W2765437031 hasVolume "20" @default.
• W2765437031 isParatext "false" @default.
• W2765437031 isRetracted "false" @default.
• W2765437031 magId "2765437031" @default.
• W2765437031 workType "article" @default.